Navigation Links
Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

"ANA598 has demonstrated potent antiviral activity and good tolerability as a single agent, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens," said James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We look forward to building upon these results to demonstrate the benefit of ANA598 when used in combination with interferon and ribavirin."

About the Phase II Study

In the Phase II study, naive genotype 1 patients will receive ANA598 or placebo in combination with Pegasys((R)) (peginterferon alfa-2a) and Copegus((R)) (ribavirin, USP) (a current standard of care, or SOC) for 12 weeks at dose levels of 200 mg or 400 mg twice daily (bid), each with a loading dose of 800 mg bid on day one. After week 12, patients will continue to receive SOC. Patients who achieve undetectable levels of virus at weeks 4 and 12 will be randomized to stop all treatment at week 24 or 48. The primary endpoint of the study is the proportion of patients with undetectable virus at week 12 (defined as complete Early Virological Response, or cEVR). Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable virus at week 4 (defined as Rapid Virol
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
2. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
7. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
8. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
9. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
10. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
(Date:11/21/2014)... CORONA, Calif. and VIENNA, Va. ... an innovative in-home care provider that operates in ... with BeClose, a leading provider of remote caregiving technology. Alta ... new and existing client receiving homecare services. ... believe this technology is the key to providing the ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 ... first-in-class aminomethylcycline (AMC). The Phase 2 study compared,safety ... of PTK 0796 to,Zyvox(R) in the treatment of ... Paratek,s trial met its primary safety and,tolerability endpoint, ...
... United Kingdom, Oct. 24 Minster,Pharmaceuticals plc (AIM: ... psychiatric disorders, is pleased to announce positive,results from ... in the prevention,of migraine with aura. The median ... in patients receiving tonabersat when compared with placebo. ...
Cached Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 2Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 3
(Date:11/24/2014)... 2014 Global electrophysiology devices market ... 2020, according to a new study by Grand ... arrhythmias clubbed with growing global geriatric population base ... still in the budding stage, the electrophysiology devices ... rates in the recent times, with physicians increasingly ...
(Date:11/24/2014)... PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology Group ... Health’s Multiple Sclerosis Center. , A graduate of ... in Neurology at Albert Einstein Medical Center in Philadelphia ... Judith Jaffe Multiple Sclerosis Center at Weill Cornell Medical ...
(Date:11/24/2014)... Olaparib functions as a chemical of the compound ... the first PARP inhibitors. Sufferers with BRCA1/2 strains may ... and are often immune to other types of melanoma ... exclusive weaknesses, as the tissues of melanoma have improved ... them to proceed splitting. This implies that medication which ...
(Date:11/24/2014)... 24, 2014 SWAccessControl.com has recently ... a matter of fact, the company is a leading online ... new magnetic locks are available at discounted prices, up to ... range of magnetic locks. This time, all of our items ... at home and abroad, so I have confidence in our ...
(Date:11/24/2014)... Eureka, CA (PRWEB) November 24, 2014 ... upcoming episode of Innovations with Ed Begley Jr, airing ... SafeHandles™ was created to provide a passive, non-invasive, replaceable, ... viewers how SafeHandles™ incorporates custom-fit shrinkable sleeves and adhesives ... areas. , “At the core of SafeHandles is ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
... , PRINCETON, N.J., July 29 ... for its second quarter ended June 30, 2009 of $0.67 per ... the sale of its centralized ECG business in 2007. Excluding the ... , "On a consolidated basis, second quarter net revenues ...
... , ARLINGTON, Va., July 29 In ... medical equipment and services (durable medical equipment) and about the ... for Homecare has developed a "Myth vs. Reality" list to ... The American Association for Homecare urges members of the media ...
... in those with known heart disease , WEDNESDAY, July 29 ... heart arteries to a standard test of blood vessel function ... to develop serious problems, a new German study indicates. , ... could help identify those who are at highest risk for ...
... , , Says ... , WASHINGTON, July 29 In today,s Washington Post, ... health care, entitled: "Crossing Our Lines: Working Together to Reform the ... expand coverage and control costs." According to Marcus, the recently released report, ...
... , , , BOSTON, July ... teenagers, it is also extremely common in adult women. Studies show ... ages of 20-29 and more than 25 percent of women between ... are far more likely to report having acne than men. While ...
... Experts warn against politicizing their placement , , WEDNESDAY, ... AEDs, can save the life of someone who is ... they be placed for maximum benefit? , In two ... , researchers focused on answering that question. , In ...
Cached Medicine News:Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 2Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 3Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 4Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 5Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 6Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 7Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 8Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 9Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 10Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 11Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 12Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 13Health News:American Association for Homecare Sets the Record Straight About Recent Home Medical Equipment Issues in the News 2Health News:American Association for Homecare Sets the Record Straight About Recent Home Medical Equipment Issues in the News 3Health News:Calcium Scan of Arteries Helps Spot Big Trouble 2Health News:Calcium Scan of Arteries Helps Spot Big Trouble 3Health News:In Case You Missed It: The Washington Post's Ruth Marcus: A Bipartisan Plan on Health Care? Try Two 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 3Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 4Health News:Put Defibrillators in High-Traffic Spots, Studies Urge 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
... tips. Each box contains 1000 tips (5 bags ... tips (4 bags of 50 tips). Also available ... per pack. Bulk Packs are sealed with a ... quick access to Gilsons Diamond Tips. Bulk Packs ...
1000 L, Bulk, blue Recommended for 500 and 1000 L pipettes....
Medicine Products: